PDUFA VI: Innovative Trial Design Proposal Includes Modeling, Simulation
This article was originally published in The Pink Sheet Daily
Executive Summary
Both ideas also will require more FDA expertise, agency tells industry.
You may also be interested in...
Should Obese Patients Be Included In Every Drug Development Program?
FDA officials question whether modeling tools can predict which drugs have different disposition in obese populations. They say physiologically-based pharmacokinetic data cannot be used as a surrogate for actual clinical trial data at this time.
Trial Simulation, Drug Selection To Be Focus Of US FDA's Drug Development Modeling Pilot
Meeting requests from sponsors that focus on safety prediction will also be prioritized.
Model-Informed Drug Development: A Risk Firms, Regulators Need To Embrace
Modeling can better inform candidate and dose selection, and support novel endpoints, labeling and postmarketing safety, even though it means stepping off the beaten path for drug development, participants say at US FDA's inaugural workshop on model-informed drug development under PDUFA VI.